IRCCS Ospedale Policlinico San Martino
IRCCS Ospedale Policlinico San Martino is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO
Sponsor Fondazione GONO G.I.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A SAFETY RUN-IN AND PHASE 2, OPEN-LABEL, MULTICENTRE, STUDY INVESTIGATING SAFETY, TOLERABILITY AND EFFECTIVENESS OF VENETOCLAX ADD IN COMBINATION AT FLUDARABINE, CYRATABINE AND IDARUBICINE IN INDUCTION THERAPY OF NEW ONSET NON-M3 ACUTE MYELOID LEUKEMIA. V-FIRST - AML1718
Sponsor Fondazione Gimema Franco Mandelli Onlus
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available4 trial-level findings · Read insights
- Between December 2018 and December 2022, 124 patients were enrolled across 17 national centers.
- Of 133 screened patients, seven failed screening because of unmet inclusion criteria (n=5) or physician decision related to FLT3 positivity (n=2).
- Two patients initially considered eligible were subsequently excluded after favorable-risk cytogenetic or molecular findings were confirmed.
- All 124 enrolled patients received the planned first induction treatment, which was administered during hospitalization.
These findings describe the trial, not the service provider’s performance or responsibility.
Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis
Sponsor Cellerys AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, Open-Label, multicentre, study investigating tolerability and efficacy of Gilteritinib in combination with fludarabine, cytarabine and idarubicin (FLAI) as induction therapy of newly diagnosed non-M3 FLT3-positive acute myeloid leukemia.GIMEMA AML2924
Sponsor Fondazione Gimema Franco Mandelli Onlus
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for IRCCS Ospedale Policlinico San Martino?
The 2026-10-09 snapshot links IRCCS Ospedale Policlinico San Martino to 4 distinct CTIS trials. Recorded services include Laboratory services, CRF REDCAP, MRI recording for site 1-06, Preparation of blood product for further IMP manufacturing (site 1-06). These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for IRCCS Ospedale Policlinico San Martino?
The most frequently recorded therapeutic areas are Gastroenterology, Haematological Malignancies, Solid Tumor Oncology. Recorded phases include Phase 1, Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to IRCCS Ospedale Policlinico San Martino conducted?
The linked trials record locations in 4 countries, including Italy, Germany, Czechia, Spain. These are trial locations, not confirmed office locations or countries where IRCCS Ospedale Policlinico San Martino delivered services.
What can this page tell me about IRCCS Ospedale Policlinico San Martino's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under IRCCS Ospedale Policlinico San Martino. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- IRCCS Ospedale Policlinico San Martino